Praluent vs Leqvio: Switching Between Alirocumab and Inclisiran

Two Drugs, One Target, Different Mechanisms

Alirocumab and inclisiran both lower LDL cholesterol by reducing circulating PCSK9, but they do it through fundamentally different molecular pathways. Understanding this distinction matters when planning a switch, because the pharmacokinetics of each drug dictate the transition window.

Alirocumab is a fully human monoclonal antibody that binds free PCSK9 protein in the bloodstream. Each injection neutralizes PCSK9 for roughly 14 days, which is why the standard dosing is 75 mg or 150 mg subcutaneously every two weeks 1. An alternative monthly regimen using 300 mg is also FDA-approved. When a patient stops alirocumab, PCSK9 levels recover and LDL-C rises back toward baseline within four to six weeks.

Inclisiran takes a different approach. It is a synthetic small interfering RNA (siRNA) conjugated to N-acetylgalactosamine, which directs it specifically to hepatocytes. Once inside the liver cell, it silences the gene that produces PCSK9, suppressing production at the source rather than blocking the protein after release 2. The effect lasts roughly six months per injection. After an initial dose and a booster at 90 days, patients receive 284 mg subcutaneously every six months.

This mechanistic difference has a practical consequence. Alirocumab clears the body in weeks. Inclisiran's silencing effect persists for months. A prescriber switching from one to the other needs to account for the asymmetry in offset and onset.

LDL-C Reduction: What the Trials Show

Both drugs produce roughly comparable LDL-C reductions when added to statin therapy, though no head-to-head trial has directly compared them.

In the ODYSSEY LONG TERM trial (N=2,341), alirocumab 150 mg every two weeks reduced LDL-C by 61% at week 24 compared to placebo, on a background of maximally tolerated statin 3. Patients started with a mean LDL-C of 122 mg/dL and reached a mean of approximately 48 mg/dL.

The ORION-10 (N=1,561) and ORION-11 (N=1,617) trials tested inclisiran 284 mg with the loading-dose schedule described above. At day 510, LDL-C was reduced by 52.3% in ORION-10 and 49.9% in ORION-11 versus placebo 2. Baseline LDL-C was 104.7 mg/dL and 105.5 mg/dL, respectively.

The numbers look similar. But the patient populations, trial designs, and primary endpoints differed enough that drawing a direct equivalence claim would be premature. What the data support is that both agents reliably halve LDL-C when layered on top of statin therapy. For patients switching between them, the expectation should be that their LDL-C nadir remains in a similar range, assuming adherence and statin background are held constant.

One variable to watch: patients who were on the lower alirocumab dose of 75 mg every two weeks may have been achieving somewhat less LDL-C reduction. Switching these patients to inclisiran 284 mg could produce a larger drop than expected, which may actually be clinically beneficial.

Cardiovascular Outcomes: The Gap That Matters Most

This is where the two drugs diverge most sharply. Alirocumab has a completed cardiovascular outcomes trial. Inclisiran does not.

ODYSSEY OUTCOMES enrolled 18,924 patients who had been hospitalized for acute coronary syndrome (ACS) one to twelve months prior 1. Patients were randomized to alirocumab or placebo on top of high-intensity statin therapy. Over a median follow-up of 2.8 years, alirocumab reduced the composite MACE endpoint (coronary heart disease death, nonfatal MI, ischemic stroke, or hospitalized unstable angina) by 15% (hazard ratio 0.85, 95% CI 0.78 to 0.93; P<0.001).

The 2018 ACC/AHA cholesterol guideline incorporated this evidence, stating that "in patients at very high risk whose LDL-C level remains ≥70 mg/dL or whose non-HDL-C level remains ≥100 mg/dL on maximally tolerated statin and ezetimibe therapy, adding a PCSK9 inhibitor is reasonable" 4.

Inclisiran has no equivalent trial result yet. ORION-4 is an ongoing randomized outcomes trial enrolling approximately 15,000 patients with atherosclerotic cardiovascular disease (ASCVD), comparing inclisiran to placebo 5. Results are anticipated but have not been published as of this writing.

This gap has a direct bearing on the switching question. A patient who is well-controlled on alirocumab and whose insurance pushes a switch to inclisiran should understand that they are moving from a drug with proven MACE reduction to one with proven LDL-C reduction but unproven cardiovascular event reduction. The LDL-C lowering hypothesis is strong. The clinical outcomes confirmation is still pending.

Dr. Kausik Ray, the principal investigator of the ORION program, stated at the 2023 European Society of Cardiology Congress: "We would anticipate based on Mendelian randomization and statin trial concordance that LDL lowering with inclisiran will translate to proportional cardiovascular benefit, but only ORION-4 will provide definitive evidence."

Dosing, Administration, and the Convenience Factor

The dosing difference between these two drugs is the single most cited reason patients and prescribers consider a switch.

Alirocumab requires self-injection using a prefilled pen. The standard schedule is every 14 days. Some patients use the 300 mg monthly option, though this involves two consecutive 150 mg injections at the same visit 6. Patients must store the pens refrigerated, remove them 30 to 40 minutes before injection to reach room temperature, and administer the injection into the abdomen, thigh, or upper arm.

Inclisiran is given as a single 284 mg subcutaneous injection by a healthcare provider in a clinical setting 7. After the day-1 dose and the day-90 booster, the schedule is every six months. Patients do not self-inject, do not store medication at home, and do not need to remember a biweekly schedule.

For patients who travel frequently, have needle anxiety about self-injection, or who simply miss doses, inclisiran's twice-yearly office-based administration can improve adherence. Real-world PCSK9 inhibitor adherence data have shown that roughly 50% of patients on self-injectable PCSK9 antibodies discontinue within two years, often due to injection burden, cost, or prior authorization friction 8. Whether inclisiran's provider-administered model changes this pattern in practice is still being evaluated.

The tradeoff is flexibility. Alirocumab can be dose-titrated (75 mg to 150 mg) based on LDL-C response. Inclisiran is a fixed 284 mg dose with no titration option.

How to Switch from Praluent to Leqvio

The transition from alirocumab to inclisiran is the more common direction, often driven by insurance formulary changes, patient preference for fewer injections, or prescriber interest in the office-administered model.

The protocol is straightforward. Because alirocumab clears within four to six weeks after the last dose, the simplest approach is to administer the first inclisiran injection at the time point when the next alirocumab dose would have been due. This avoids any gap in PCSK9 suppression. The patient skips their next scheduled Praluent injection and instead receives the first Leqvio dose in the prescriber's office.

A practical switching protocol:

1. Confirm that inclisiran is covered under the patient's medical benefit (it is typically billed under Part B or the medical benefit, not the pharmacy benefit, because it is administered by a provider).
2. Administer inclisiran 284 mg subcutaneously on the day the next alirocumab injection would have been scheduled.
3. Schedule the second inclisiran dose 90 days after the first.
4. Schedule subsequent doses every six months thereafter.
5. Recheck a fasting lipid panel four to eight weeks after the second inclisiran dose to confirm LDL-C remains at goal.

There is no washout period needed. Both drugs suppress PCSK9 through non-overlapping mechanisms, and brief overlap during the transition poses no known safety risk. The European Atherosclerosis Society (EAS) has noted that "transitioning between PCSK9-lowering therapies can be managed without interruption in treatment, with timing guided by the pharmacokinetics of the outgoing agent" 9.

How to Switch from Leqvio to Praluent

This direction is less common but arises in specific situations: a patient needs dose titration not available with inclisiran, experiences injection-site reactions to inclisiran, prefers the proven cardiovascular outcomes data behind alirocumab, or loses medical benefit coverage for inclisiran.

The challenge here is inclisiran's long duration of action. After the last inclisiran dose, PCSK9 suppression persists for roughly six months. Starting alirocumab immediately would layer antibody-based PCSK9 blockade on top of existing siRNA-mediated PCSK9 gene silencing. While no safety signal has been identified from this overlap, it also has not been formally studied.

Two approaches are reasonable:

Immediate start. Begin alirocumab at the next scheduled inclisiran dose date (six months after the last injection). This provides smooth coverage. The residual inclisiran effect will taper during the first few weeks of alirocumab therapy.

Delayed start with monitoring. If the concern is cost or insurance, the prescriber may choose to wait until LDL-C begins rising (typically three to four months after the last inclisiran dose), then initiate alirocumab. This requires a lipid check at month three to four to catch the inflection point.

Either way, the starting dose of alirocumab should be based on the patient's LDL-C at the time alirocumab is initiated. If LDL-C is still substantially suppressed from residual inclisiran effect, 75 mg every two weeks may be sufficient, with up-titration to 150 mg at four to eight weeks if needed 6.

Safety Profiles: What Changes When You Switch

Both drugs are well tolerated. The safety data from clinical trials show broadly similar adverse event profiles, with injection-site reactions being the most commonly reported drug-specific side effect.

In the ORION-10 and ORION-11 trials, injection-site reactions occurred in 5.0% of inclisiran-treated patients versus 0.7% on placebo 2. These were predominantly mild and transient. In ODYSSEY OUTCOMES, local injection-site reactions occurred in 3.8% of alirocumab patients versus 2.1% with placebo 1.

Neither drug carries a signal for neurocognitive effects, new-onset diabetes, or hepatotoxicity at rates exceeding placebo. The FDA labels for both agents list nasopharyngitis, influenza-like symptoms, and upper respiratory tract infection among common adverse events, though these occurred at similar rates in treatment and placebo arms 6 7.

One consideration specific to switching: a patient who developed anti-drug antibodies to alirocumab (reported in approximately 5% of treated patients, though neutralizing antibodies are rare) would not be expected to have cross-reactivity with inclisiran, because inclisiran is not a protein and does not elicit the same immune response. This makes inclisiran a logical next step for the small subset of patients who lost efficacy on alirocumab due to immunogenicity.

Insurance, Cost, and Benefit Design Differences

The economic architecture around these two drugs differs in ways that affect switching decisions, sometimes more than the clinical data.

Alirocumab is dispensed through specialty pharmacies and billed under the pharmacy benefit (commercial plans) or Medicare Part D. The wholesale acquisition cost is approximately $5,850 per year. Most commercial patients use manufacturer copay assistance programs to reduce out-of-pocket costs 6.

Inclisiran is administered in the provider's office and billed under the medical benefit (commercial plans) or Medicare Part B. The list price is approximately $3,250 per injection, or $6,500 per year after the loading-dose year (which includes three injections and costs approximately $9,750) 7. Because it falls under the medical benefit, patients may face different cost-sharing structures, and prior authorization processes may route through different channels.

The American College of Cardiology's 2022 Expert Consensus Decision Pathway on the role of nonstatin therapies noted that "benefit design, formulary placement, and prior authorization requirements vary substantially for PCSK9-targeted therapies, and clinicians should consider these practical barriers when selecting a specific agent" 10.

For patients on Medicare, the distinction between Part B (medical benefit) and Part D (pharmacy benefit) can mean the difference between 20% coinsurance with no coverage gap and the Part D coverage gap. This financial consideration alone drives some switches.

Who Should Stay on Their Current Agent

Not every patient benefits from switching. Several clinical scenarios favor staying put.

Patients who are at LDL-C goal on alirocumab and tolerate the biweekly injections without difficulty have no clinical reason to switch. The proven MACE reduction from ODYSSEY OUTCOMES applies to their current regimen but not yet to inclisiran.

Patients who require dose flexibility should remain on alirocumab. The ability to titrate between 75 mg and 150 mg every two weeks allows prescribers to find the lowest effective dose, an option inclisiran's fixed-dose design does not offer.

Conversely, patients who are poorly adherent to biweekly alirocumab injections may achieve better sustained LDL-C control on twice-yearly inclisiran administered in a clinical setting 8. For these patients, the best PCSK9 therapy is the one they actually receive consistently.

Dr. Peter Wilson, professor of medicine and public health at Emory University, has stated: "The choice between a PCSK9 monoclonal antibody and inclisiran often comes down to patient-specific factors, adherence patterns, and payer logistics rather than efficacy differences, because both agents are potent LDL-C lowerers."

Patients within 12 months of an ACS event who are being started on PCSK9-targeted therapy for the first time may have a stronger rationale for alirocumab, given that ODYSSEY OUTCOMES specifically enrolled post-ACS patients and demonstrated benefit in this exact population 1.